Editas Medicine(us:EDIT)

1.13

-2.59%

Updated on 2025-04-02

Open:1.15
Close:1.13
High:1.18
Low:1.12
Prev Close:1.16
Volume:2.13M
Turnover:2.44M
Turnover Ratio:2.56%
Shares:82.98M
MarketCap:93.76M
DateTotalTotal SharesTotal RatioNewIncreasedDecreased
2024-06-302645627020368.26%4664106
2024-03-312516787119182.53%367393
2023-12-312535878829271.90%3851108
2023-09-302526151386075.32%2575100
2023-06-302656247862576.55%427486
2023-03-312635205639175.45%286999
2022-12-312945403103478.48%4263118
2022-09-302824791294769.68%417099
dateorgNametotalratiochangeShareschangeRatio
2024-06-30Vanguard Group Inc80326049.74%-522993-6.11%
2024-06-30Blackrock Inc.77825179.44%-50264-0.64%
2024-06-30Deep Track Capital, Lp60000007.28%4727108.55%
2024-06-30State Street Corp45909135.57%-4169238-47.59%
2024-06-30Millennium Management Llc24596292.98%2230129.97%
2024-06-30Dimensional Fund Advisors Lp23450542.84%-262711-10.07%
2024-06-30Geode Capital Management, Llc19658222.38%210591.08%
2024-06-30Pictet Asset Management Holding Sa14272771.73%-834368-36.89%
2024-06-30Goldman Sachs Group Inc12186871.48%-182245-13.01%
2024-06-30Woodline Partners Lp9704911.18%754918.44%

About

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Address:11 Hurley Street

Market Movers